Abstract: Objective To analyze the clinical treatment effect and safety of lamivudine and Fuzhenghuayu capsule on patients with compensated cirrhosis of hepatitis B. Methods Total of 90 patients with compensated hepatitis B cirrhosis were chosen from our outpatient service and hospitalized patients from March 2011 to September 2013. All patients were randomly divided into two groups: combination group (treated with lamivudine and Fuzhenghuayu capsule), and control group (treated with lamivudine). Each group had 45 patients and the course of treatment was 12 months. The indexes of ALT, HBV DNA, TBil and serum hepatic fibrosis markers (HA, PⅢNP, LN, CⅣ) were recorded. The indexes of liver functions, HBV DNA conversion rate, HBeAg conversion rate and drug resistant rate were analyzed. Results The indexes of ALT, HBV DNA, TBil and serum hepatic fibrosis markers (HA, PⅢNP, LN, CⅣ) in two groups all decreased and the differences were statistically significant (P ＜ 0.05). The indexes of ALT normalization rate, HBV DNA conversion rate and drug resistant rate in combination group were significantly higher than those in the control group (P ＜ 0.05). The HBeAg conversion rate had no statistical difference in both groups (P ＞ 0.05). Conclusions The combination use of lamivudine and Fuzhenghuayu capsule can relieve liver function, postpone liver fibrosis and decrease drug-resistant rate of patients with compensated cirrhosis of hepatits B.